Nirsevimab-resistant respiratory syncytial virus strains are rare but there.

Respiratory syncytial virus (RSV) was discovered in 1956, 1 Blount Jr, RE Morris JA Savage RE Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med. 1956; 92: 544-549 Crossref PubMed Scopus (291) Google Scholar isolated from an infant with a respiratory illness in 1957, 2 Chanock R Roizman B Myers R Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg. 1957; 66: 281-290 PubMed Google Scholar found to cause severe respiratory disease in immunocompromised individuals in 1985, 3 Padman R Bye MR Schidlow DV Zaeri N Severe RSV bronchiolitis in an immunocompromised child. Clin Pediatr (Phila). 1985; 24: 719-721 Crossref PubMed Scopus (8) Google Scholar and found to cause disease in those older than 65 years in 2005. 4 Falsey AR Hennessey PA Formica MA Cox C Walsh EE Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005; 352: 1749-1759 Crossref PubMed Scopus (1439) Google Scholar Today, RSV is recognised as the leading cause of hospital treatment for children younger than 1 year and the second most important respiratory pathogen for those older than 65 years, after influenza virus. 4 Falsey AR Hennessey PA Formica MA Cox C Walsh EE Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005; 352: 1749-1759 Crossref PubMed Scopus (1439) Google Scholar In 1998, the first monoclonal antibody to prevent RSV disease in infants and young children, palivizumab, was approved by the US Food and Drug Administration (FDA). Palivizumab has been used in some countries to protect babies born prematurely or with other underlying problems, during their first RSV season. Palivizumab neutralises RSV by binding to the virus' fusion glycoprotein in the virion membrane and interfering with its function. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing dataThe nirsevimab binding site was highly conserved between 1956 and 2021. Nirsevimab escape variants were rare and have not increased over time. Full-Text PDF